title: HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial.
abstract: OBJECTIVE
  The aim of this study was to demonstrate whether and how HR (Venoruton(1000), Paroven, 0-[beta-hydroxyethyl]-rutosides) and Daflon (diosmin, 500 mg) were comparatively effective in improving the microcirculation in venous hypertension and microangiopathy.
  
  
  METHODS
  A group of 90 patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis were included. After informed consent, patients were randomized into a Venoruton and a Daflon (DF) group: patients in the Venoruton group received oral HR (2 g/day for 8 weeks); those in the Daflon group received three 500-mg tablets daily every 8 hours. The two groups were comparable for age and sex distribution. The mean age was 41 years (SD +/- 11) in the Venoruton group (46 patients) and 41.3 (SD +/- 12) in the DF group (44 patients).
  
  
  RESULTS
  There were no differences in microcirculatory parameters between the Venoruton and DF treatment groups at inclusion. There was no significant change between inclusion and measurements at 8 weeks in the DF group. In comparison, a significant decrease (P < .05) in RF (resting skin flux) and RAS (rate of ankle swelling) was observed in the Venoruton group (P < .001). The decrease in capillary filtration was associated with improvement in signs and symptoms (measured by an analogue scale line) (P < .05). Symptomatic improvement was clinically and statistically significant and important only in the Venoruton group. No side effects and no drop-outs were observed.
  
  
  CONCLUSIONS
  Venous microangiopathy was improved by the treatment with Venoruton. The comparison with Daflon indicates that HR is comparatively more effective both on microcirculatory parameters and on signs and symptoms.
authors.affiliation: Irvine2 Vascular Laboratory and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Belcaro
authors.forename: M R
authors.initials: MR
authors.lastname: Cesarone
authors.forename: P
authors.initials: P
authors.lastname: Bavera
authors.forename: A
authors.initials: A
authors.lastname: Ricci
authors.forename: S
authors.initials: S
authors.lastname: Renton
authors.forename: M
authors.initials: M
authors.lastname: Leon
authors.forename: E
authors.initials: E
authors.lastname: Ippolito
authors.forename: M
authors.initials: M
authors.lastname: Dugall
authors.forename: G
authors.initials: G
authors.lastname: Acerbi
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004145:Diosmin / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000191:economics / Q000473:pathology*
chemical_list: D006896:Hydroxyethylrutoside; D004145:Diosmin; C005865:troxerutin